# EDGAR Filing Document

**Accession Number:** 0001722964
**File Stem:** 0001104659-25-068099
**Filing Date:** 2025-7
**Character Count:** 6452
**Document Hash:** 73b9c20a95ee7066b7128e29c73df665
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-068099.hdr.sgml**: 20250715

**ACCESSION NUMBER**: 0001104659-25-068099

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250711

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250715

**DATE AS OF CHANGE**: 20250715

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Y-mAbs Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001722964
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474619612
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38650
- **FILM NUMBER:** 251124969

**BUSINESS ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 301
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 646-885-8505

**MAIL ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 301
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

?xml version='1.0' encoding='ASCII'?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of** 

**the Securities Exchange Act of 1934** 

**Date of report (Date of earliest event reported): July 11, 2025**

**Y-MABS THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38650** | **47-4619612** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**202 Carnegie Center Drive**

**Suite 301**

**Princeton, New Jersey 08540** 

**(Address of principal executive offices) (Zip Code)** 

**(646) 885-8505** 

**(Registrant's telephone number, include area code)** 

**N/A** 

**(Former Name or Former telephone number, including area code, of agent for service)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading Symbol** | **Name of each exchange on which<br> registered:** |
| Common Stock, $0.0001 par value | YMAB | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders** |

---

On July 11, 2025, Y-mAbs Therapeutics, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following three proposals: (1) the election of one Class I director, David N. Gill, to hold office until the Company's 2028 annual meeting of stockholders or until the election and qualification of his successor or his earlier death, resignation or removal ("Proposal 1"); (2) the ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 ("Proposal 2"); and (3) the approval, in a non-binding advisory vote, of the compensation of the Company's named executive officers as disclosed in the proxy statement ("Proposal 3"). Each of these proposals is described in greater detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on May 30, 2025. The final results of the voting on each proposal are set forth below.

***Proposal 1 - Election of Director***

The Company's stockholders elected the person listed below as a director, to hold office until the Company's 2028 annual meeting of stockholders or until the election and qualification of his successor or his earlier death, resignation or removal. The votes cast were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Nominees** | **For** | **For** | **Withheld** | **Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
| David N. Gill |  | 18926572 |  | 11924775 |  | 3133377 |

---

***Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm***

The Company's stockholders approved Proposal 2. The votes cast were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** |
|  | 32884437 |  | 1097151 |  | 3136 |

---

***Proposal 3 – Advisory Vote on the Compensation of the Named Executive Officers***

The Company's stockholders approved Proposal 3. The votes cast were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 27011027 |  | 3838565 |  | 1755 |  | 3133377 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Y-MABS THERAPEUTICS, INC. | Y-MABS THERAPEUTICS, INC. |
| Date: July 15, 2025 | By: | /s/ Michael Rossi |
|  |  | Michael Rossi |
|  |  | President and Chief Executive Officer |

---